Pfizer

ELREXFIO

Manufacturer:

Pfizer

Elrexfio HCPCS:

C9165

HCPCS Code Descriptor:

Injection, elranatamab-bcmm, 1 mg

Category:

C Code

Elrexfio NDCs:

00069-4494-02, 00069-2522-02

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Elrexfio:

ELREXFIO is an Oncology drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The C Code: C9165 is aligned to the drug ELREXFIO.

Elrexfio is a subcutaneous injection used to treat a type of blood cancer called multiple myeloma. Multiple myeloma affects plasma cells made in the bone marrow. Elfrexio is a bispecific antibody that binds the the surface of the cancer cells, thus encouraging your immune system to attack and kill the cancer. Elrexfio is often prescribed to adults who relapsed or refractory multiple myeloma, and for whom other types of treatment have not worked.

ACCESS PRICING AND MORE BY REGISTERING

C9165 Added Date:

January 1, 2024

C9165 Effective Date:

January 1, 2024

C9165 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Elrexfio billing and coding information.
Elrexfio patient assistance information can be found through Pfizer Oncology Together at the URL: https://www.elrexfio.com/navigating-support-financial-resources
ELREXFIO prescribing information can be found at the link below:
Information regarding ELREXFIO’s side effects can be found at MedlinePlus